aTYR PHARMA INC Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
aTYR PHARMA INC (ATYR) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2023-03-14
- aTYR PHARMA INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2022 was $0.00.
- aTYR PHARMA INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
- aTYR PHARMA INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2020 was $0.00.
- aTYR PHARMA INC other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2019 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-14 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-15 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-24 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-26 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |